Human immunodeficiency virus-associated neurocognitive disorders mind the gap

Annals of Neurology

Volumn 67, Issue 6, 2010, Pages 699-714

  McArthur, Justin C ^a,b   Steiner, Joseph ^a   Sacktor, Ned ^a   Nath, Avi ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR ANTAGONIST; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VICRIVIROC; ZALCITABINE; ZIDOVUDINE;

AGING; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VIREMIA;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COGNITION DISORDERS; HIV INFECTIONS; HUMANS;

EID: 77952940200     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22053     Document Type: Review

References (187)

1. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005;4:543-555.
2. He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997;385:645-649.
3. Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. Nat Med 1996;2:1174-1178. (Pubitemid 26375391)
4. Steinman RM. DC-SIGN: a guide to some mysteries of dendritic cells. Cell 2000;100:491-494.
5. Burton GF, Keele BF, Estes JD, et al. Follicular dendritic cell contributions to HIV pathogenesis. Semin Immunol 2002;14:275-284. (Pubitemid 34969896)
6. Brown A, Zhang H, Lopez P, et al. In vitro modeling of the HIV-macrophage reservoir. J Leukoc Biol 2006;80:1127-1135.
7. Lamers SL, Salemi M, Galligan DC, et al. Extensive HIV-1 intra-host recombination is common in tissues with abnormal histopathology. PLoS One 2009;4:e5065.
8. Nath A, Hartloper V, Furer M, Fowke KR. Infection of human fetal astrocytes with HIV-1: viral tropism and the role of cell to cell contact in viral transmission. J Neuropathol Exp Neurol 1995;54:320-330.
9. Churchill MJ, Figueiredo A, Cowley D, et al. Transcriptional activity of blood- and cerebrospinal fluid-derived nef/long-terminal repeat sequences isolated from a slow progressor infected with nef-deleted human immunodeficiency virus type 1 (HIV-1) who developed HIV-associated dementia. J Neurovirol 2006;12:219-228. (Pubitemid 44574597)
10. Sacktor N, Nakasujja N, Robertson K, Clifford DB. HIV-associated cognitive impairment in sub-Saharan Africa - the potential effect of clade diversity. Nat Clin Pract Neurol 2007;3:436-443. (Pubitemid 47202500)
11. Sacktor N, Nakasujja N, Skolasky RL, et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 2009;49:780-786.
12. Mishra M, Vetrivel S, Siddappa NB, et al. Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol 2008;63:366-376. (Pubitemid 351499866)
13. Michael NL, Vahey M, Burke DS, Redfield RR. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. J Virol 1992;66:310-316.
14. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
15. Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 2009;200:984-990.
16. Alexaki A, Wigdahl B. HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog 2008;4:e1000215.
17. Vehmas A, Lieu J, Pardo CA, et al. Amyloid precursor protein expression in circulating monocytes and brain macrophages from patients with HIV-associated cognitive impairment. J Neuroimmunol 2004;157:99-110.
18. Masliah E, Achim CL, Ge N, et al. Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 1992;32:321-329.
19. Pardridge WM. Targeting neurotherapeutic agents through the blood-brain barrier. Arch Neurol 2002;59:35-40.
20. Nguyen TP, Soukup VM, Gelman BB. Persistent hijacking of brain proteasomes in HIV-associated dementia. Am J Pathol 2010;176:893-902.
21. Adamson CS, Freed EO. Recent progress in antiretrovirals - lessons from resistance. Drug Discov Today 2008;13:424-432.
22. Panel on Clinical Practices for Treatment of HIV. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents - April 7, 2005: Washington, DC: Department of Health and Human Services, 2005.
23. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009;4:e5575.
24. Aquaro S, Caliò R, Balzarini J, et al. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 2002;55:209-225. (Pubitemid 34718126)
25. Sacktor N, Nakasujja N, Skolasky RL, et al. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009;72:165-170.
26. Dore GJ, McDonald A, Li Y, et al. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003;17:1539-1545. (Pubitemid 36900555)
27. Nakasujja N, Musisi S, Robertson K, et al. Human immunodeficiency virus neurological complications: an overview of the Ugandan experience. J Neurovirol 2005;11(suppl 3):26-29.
28. Wong MH, Robertson K, Nakasujja N, et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 2007;68:350-355. (Pubitemid 46184210)
29. Wright EJ, Nunn M, Joseph J, et al. NeuroAIDS in the Asia Pacific Region. J Neurovirol 2008; Nov 27:1-9. [Epub ahead of print].
30. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol 2004;157:3-10.
31. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Neurology 1993;43:2245-2252.
32. Wright EJ, Nunn M, Joseph J, et al. NeuroAIDS in the Asia Pacific region. J Neurovirol 2008;1-9.
33. Heaton R, Franklin DO, Woods S, et al for the CHARTER Group. HIV-associated neurocognitive disorders (HAND) persist in the era of potent antiretroviral therapy: the CHARTER study. Neurology (in press).
34. Lopardo GD, Bissio E, Iannella Mdel C, et al. Good neurocognitive performance measured by the international HIV dementia scale in early HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52:488-492.
35. Cole MA, Margolick JB, Cox C, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology 2007;69:2213-2220. (Pubitemid 350294676)
36. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21:1915-1921. (Pubitemid 47329768)
37. Sevigny JJ, Albert SM, McDermott MP, et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol 2007;64:97-102.
38. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006;66:1447-1450. (Pubitemid 43739663)
39. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS [published online ahead of print Dec 7, 2009].
40. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007;8:33-44.
41. Janssen RS, Cornblath DR, Epstein LG, et al. Human immunodeficiency virus (HIV) infection and the nervous system: report from the American Academy of Neurology AIDS Task Force. Neurology 1989;39:119-122.
42. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002;8(suppl 2):115-121.
43. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 2002;59:1944-1950.
44. Mayeux R, Stern Y, Tang MX, et al. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology 1993;43:176-182.
45. Sacktor NC, Bacellar H, Hoover DR, et al. Psychomotor slowing in HIV infection predicts increased risk of dementia, AIDS, and death. J Neurovirol 1996;2:48.
46. Cherner M, Masliah E, Ellis RJ, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002;59:1563-1567.
47. Power C. HIV dementia. Paper presented at: World Congress of Neurology; October 2009, Bangkok, Thailand.
48. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999;52:607-613.
49. Chiesi A, Seeber AC, Dally LG, et al. AIDS dementia complex in the Italian National AIDS Registry: temporal trends (1987-1993) and differential incidence according to mode of transmission of HIV-1 infection. J Neurol Sci 1996;144:107-113.
50. Brew BJ, Letendre SL. Biomarkers of HIV related central nervous system disease. Int Rev Psychiatry 2008;20:73-88.
51. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004;63:2084-2090.
52. Ragin AB, Ochs R, Scheidegger R, Bruce A. Biomarkers of neurological status in HIV infection: a 3-year study. Proteomics Clin Appl 2010;295-303.
53. Valcour V, Shikuma C, Shiramizu B, et al. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol 2004;157:197-202. (Pubitemid 39576655)
54. Corder EH, Robertson K, Lannfelt L, et al. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med 1998;4:1182-1184.
55. Quasney MW, Zhang Q, Sargent S, et al. Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. Ann Neurol 2001;50:157-162.
56. Singh KK, Ellis RJ, Marquie-Beck J, et al. CCR2 polymorphisms affect neuropsychological impairment increased frequency of the tumor necrosis factor-alpha-308 A allele in HIV-1-infected adults with human immunodeficiency virus dementia. J Neuroimmunol 2004;157:185-192.
57. Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A 2002;99:13795-13800.
58. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433-439.
59. Letendre SL, Cherner M, Ellis RJ, et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 2005; 19(suppl 3):S72-S78.
60. Lu Y, Robinson M, Zhang FJ. Human immunodeficiency virus and hepatitis C virus co-infection: epidemiology, natural history and the situation in China. Chin Med J (Engl) 2009;122:93-97.
61. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002;35:440-446.
62. Morgello S, Estanislao L, Ryan E, et al. Effects of hepatic function and hepatitis C virus on the nervous system assessment of advanced-stage HIV-infected individuals. AIDS 2005;19(suppl 3):S116-S122. (Pubitemid 41682178)
63. Perry W, Carlson MD, Barakat F, et al. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS 2005;19(suppl 3):S79-S84. (Pubitemid 41682173)
64. Meyerhoff DJ, Bloomer C, Cardenas V, et al. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology 1999;52:995-1003. (Pubitemid 29161610)
65. Forton DM, Allsop JM, Main J, et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001;358:38-39. (Pubitemid 32709741)
66. Letendre S, Paulino AD, Rockenstein E, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007;196:361-370.
67. Epstein LG, Boucher CA, Morrison SH, et al. Persistent human immunodeficiency virus type 1 antigenemia in children correlates with disease progression. Pediatrics 1988;82:919-924.
68. Mintz M, Rapaport R, Oleske JM, et al. Elevated serum levels of tumor necrosis factor are associated with progressive encephalopathy in children with acquired immunodeficiency syndrome. Am J Dis Child 1989;143:771-774. (Pubitemid 19172092)
69. Brew BJ. HIV, the brain, children, HAART and 'neuro-HAART': a complex mix. AIDS 2009;23:1909-1910.
70. da Cunha A, Mintz M, Eiden LE, Sharer LR. A neuronal and neuroanatomical correlate of HIV-1 encephalopathy relative to HIV-1 encephalitis in HIV-1-infected children. J Neuropathol Exp Neurol 1997;56:974-987. (Pubitemid 27386127)
71. Sánchez-Ramòn S, Bellòn JM, Resino S, et al. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children. Pediatrics 2003;111:E168-E175.
72. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004;18(suppl 1):S75-S78.
73. Kipnis J, Derecki NC, Yang C, Scrable H. Immunity and cognition: what do age-related dementia, HIV-dementia and 'chemo-brain' have in common? Trends Immunol 2008;29:455-463.
74. Brynskikh A, Warren T, Zhu J, Kipnis J. Adaptive immunity affects learning behavior in mice. Brain Behav Immun 2008;22:861-869.
75. Tozzi V, Uccella I, Larussa D, et al. Characteristics and factors associated with HIV-1 related neurocognitive disorders during HAART era. J Neurovirol 2003;9(suppl 3):82. Abstract H.64.
76. Langford D, Marquie-Beck J, de Almeida S, et al. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol 2006;12:100-107. (Pubitemid 44574601)
77. Venkataramana A, Pardo CA, McArthur JC, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006;67:383-388. (Pubitemid 44214957)
78. Langford TD, Letendre SL, Marcotte TD, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 2002;16:1019-1029.
79. Langford TD, Letendre SL, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 2003;13:195-210. (Pubitemid 36460820)
80. Schmidbauer M, Budka H, Okeda R, et al. Multifocal vacuolar leucoencephalopathy: a distinct HIV-associated lesion of the brain. Neuropathol Appl Neurobiol 1990;16:437-443. (Pubitemid 20334865)
81. Valcour V, Watters MR, Williams AE, et al. Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. J Neurovirol 2008;14:362-367. (Pubitemid 352762875)
82. McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997;42:689-698.
83. Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997;175:963-966. (Pubitemid 27142978)
84. McArthur JC, McDermott MP, McClernon D, et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004;61:1687-1696.
85. Ellis RJ, Gamst AC, Capparelli E, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000;54:927-936.
86. Marra CM, Lockhart D, Zunt JR, et al. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003;60:1388-1390. (Pubitemid 36461005)
87. Letendre SL, Ellis RJ, Everall I, et al. Neurologic complications of HIV disease and their treatment. Top HIV Med 2009;17:46-56.
88. Price RW, Epstein LG, Becker JT, et al. Biomarkers of HIV-1 CNS infection and injury. Neurology 2007;69:1781-1788.
89. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990;28:556-560.
90. Yilmaz A, Price RW, Spudich S, et al. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr 2008;47:168-173.
91. Brew BJ, Bhalla RB, Fleisher M, et al. Cerebrospinal fluid Beta-2 microglobulin in patients infected with human immunodeficiency virus. Neurology 1989;39:830-834.
92. Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebro-spinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 1991;29:202-209.
93. Towfighi A, Skolasky RL, St Hillaire C, et al. CSF soluble Fas correlates with the severity of HIV-associated dementia. Neurology 2004;62:654-656.
94. Turchan J, Pocernich CB, Gairola C, et al. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 2003;60:307-314.
95. Haughey NJ, Cutler RG, Tamara A, et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 2004;55:257-267.
96. Nath A, Schiess N, Venkatesan A, et al. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 2008;20:25-31.
97. Li W, Malpica-Llanos TM, Gundry R, et al. Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity. Neurology 2008;70(19 pt 2):1753-1762.
98. Taylor MD, van der Werf N, Harris A, et al. Early recruitment of natural CD4+ Foxp3+ Treg cells by infective larvae determines the outcome of filarial infection. Eur J Immunol 2009;39:192-206.
99. Cohen RA, Harezlak J, Schifitto G, et al. Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol 2010;16:25-32.
100. Cardenas V, Meyerhoff D, Studholme C, et al. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol [published online ahead of print June 4, 2009].
101. Ragin AB, Wu Y, Ochs R, et al. Serum matrix metalloproteinase levels correlate with brain injury in human immunodeficiency virus infection. J Neurovirol [published online ahead of print May 14, 2009].
102. Ragin A. Biomarkers of neurological status in HIV infection: a 3-year study. Proteomics Clin Appl 2009;4:295-303.
103. Chang L. Cerebral metabolic abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 1999;52:100-108.
104. Paul RH, Ernst T, Brickman AM, Yiannoutsos CT, et al. Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among non-demented individuals infected with HIV. J Int Neuropsychol Soc 2008;14:725-733.
105. Chang L, Witt M, Eric M, et al. Cerebral metabolite changes during the first nine months after HAART. Neurology 2001;56: A474. Abstract S63.001.
106. Zink MC, Spelman JP, Robinson RB, Clements JE. SIV infection of macaques - modeling the progression to AIDS dementia. J Neurovirol 1998;4:249-259.
107. Zink MC, Amedee AM, Mankowski JL, et al. Pathogenesis of SIV encephalitis. Selection and replication of neurovirulent SIV. Am J Pathol 1997;151:793-803.
108. Dinoso JB, Rabi SA, Blankson JN, et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009;83:9247-9257.
109. Ohshima S, Kobayashi H, Yamaguchi N, et al. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum 2002;46:1094-1101.
110. Burdo TH, Wood MR, Fox HS. Osteopontin prevents monocyte recirculation and apoptosis. J Leukoc Biol 2007;81:1504-1511.
111. Vago L, Bonetto S, Nebuloni M, et al. Pathological findings in the central nervous system of AIDS patients on assumed antiretroviral therapeutic regimens: retrospective study of 1597 autopsies. AIDS 2002;16:1925-1928.
112. Everall I, Barnes H, Spargo E, Lantos P. Assessment of neuronal density in the putamen in human immunodeficiency virus (HIV) infection. Application of stereology and spatial analysis of quadrats. J Neurovirol 1995;1:126-129.
113. Williams K, Alvarez X, Lackner AA. Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia 2001;36:156-164.
114. Takahashi K, Wesselingh SL, Griffin DE, et al. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol 1996;39:705-711. (Pubitemid 26183806)
115. Thompson KA, Churchill MJ, Gorry PR, et al. Astrocyte specific viral strains in HIV dementia. Ann Neurol 2004;56:873-877.
116. Ma M, Geiger JD, Nath A. Characterization of a novel binding site for the human immunodeficiency virus type 1 envelope protein gp120 on human fetal astrocytes. J Virol 1994;68:6824-6828. (Pubitemid 24294942)
117. Di Rienzo AM, Aloisi F, Santarcangelo AC, et al. Virological and molecular parameters of HIV-1 infection of human embryonic astrocytes. Arch Virol 1998;143:1599-1615. (Pubitemid 28417790)
118. Kure K, Llena JF, Lyman WD, et al. Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. Hum Pathol 1991;22:700-710.
119. Brew BJ, Rosenblum M, Cronin K, Price RW. AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol 1995;38:563-570.
120. Vargas D, Nascimbene C, Lee A. Chemokine and cytokine profiling by protein array technology shows the basal ganglia as the most affected area in HIV dementia. Abstract presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 23, 2005; Boston, MA.
121. Anthony IC, Bell JE. The neuropathology of HIV/AIDS. Int Rev Psychiatry 2008;20:15-24.
122. Thompson KA, McArthur JC, Wesselingh SL. Correlation between disease progression and astrocyte apoptosis in HIV-associated dementia. Ann Neurol 2001;49:745-752.
123. Ketzler S, Weis S, Haug H, Budka H. Loss of neurons in the frontal cortex in AIDS brains. Acta Neuropathol 1990;80:92-94. (Pubitemid 20150001)
124. Masliah E, Ge N, Achim CL, et al. Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol 1992;51:585-593.
125. Asare E, Dunn G, Glass J, et al. Neuronal pattern correlates with the severity of human immunodeficiency virus-associated dementia complex. Usefulness of spatial pattern analysis in clinicopathological studies. Am J Pathol 1996;148:31-38. (Pubitemid 26019640)
126. Barker PB, Lee RR, McArthur JC. AIDS dementia complex: evaluation with proton MR spectroscopic imaging. Radiology 1995;195:58-64.
127. Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of HIV in the brain: correlations with HIV-associated dementia. Ann Neurol 1995;38:755-762.
128. Wesselingh SL, Takahashi K, Glass JD, et al. Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase polymerase chain reaction in situ hybridization and immunohistochemistry. J Neuroimmunol 1997;74:1-8. (Pubitemid 27128971)
129. Glass JD, Johnson RT. Human immunodeficiency virus and the brain. Annu Rev Neurosci 1996;19:1-26.
130. Acunta P, Kamat A, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. Public Library of Science 2008, 3:e2516.
131. McCombe JA, Auer RN, Maingat FG, et al. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology 2009;72:835-841.
132. Wang T, Allie R, Conant K, et al. Granzyme B mediates neuro-toxicity through a G-protein-coupled receptor. FASEB J 2006;20:1209-1211.
133. Griffin DE. Cytokines in the brain during viral infection: clues to HIV-associated dementia. J Clin Invest 1997;100:2948-2951.
134. Adamson DC, McArthur JC, Dawson TM, Dawson VL. Rate and severity of HIV-associated dementia: correlations with gp41 and iNOS. Mol Med 1999;5:98-109.
135. Heyes MP, Ellis RJ, Ryan L, et al. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. Brain 2001;124(pt 5):1033-1042.
136. Smith DG, Guillemin GJ, Pemberton L, et al. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol 2001;7:56-60. (Pubitemid 32904359)
137. Yong VW, Krekoski CA, Forsyth PA, et al. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998;21:75-80.
138. Vos CM, Sjulson L, Nath A, et al. Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures. Exp Neurol 2000;163:324-330. (Pubitemid 30399081)
139. Patton BL, Chiu AY, Sanes JR. Synaptic laminin prevents glial entry into the synaptic cleft. Nature 1998;393:698-701.
140. Nath A, Geiger J. Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog Neurobiol 1998;54:19-33. (Pubitemid 28049817)
141. Chauhan A, Turchan J, Pocernich C, et al. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem 2003;278:13512-13519. (Pubitemid 36800126)
142. Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 2002;25:537-562.
143. Nath A, Conant K, Chen P, et al. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 1999;274:17098-17102.
144. Bruce-Keller AJ, Chauhan A, Dimayuga FO, et al. Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J Neurosci 2003;23:8417-8422. (Pubitemid 37129659)
145. Cheng-Mayer C, Levy JA. Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol 1988;23:S58-S61.
146. Chesebro B, Wehrly K, Nishio J, Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 1992;66:6547-6554.
147. Chiodi F, Valentin A, Keys B, et al. Biological characterization of paired human immunodeficiency virus type 1 isolates from blood and cerebrospinal fluid. Virology 1989;173:178-187. (Pubitemid 19268261)
148. Power C, McArthur JC, Nath A, et al. Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol 1998;72:9045-9053. (Pubitemid 28471848)
149. Johnston JB, Zhang K, Silva C, et al. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 2001;49:230-241. (Pubitemid 32157999)
150. Meucci O, Fatatis A, Simen AA, et al. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U S A 1998;95:14500-14505.
151. Zhang K, McQuibban GA, Silva C, et al. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci 2003;6:1064-1071. (Pubitemid 37186198)
152. Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. Ann Neurol 1997;42:963-972. (Pubitemid 28008427)
153. Everall IP, Heaton RK, Marcotte TD, et al. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 1999;9:209-217.
154. Moore DJ, Masliah E, Rippeth JD, et al. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS 2006;20:879-887. (Pubitemid 43731570)
155. Wiley CA, Soontornniyomkij V, Radhakrishnan L, et al. Distribution of brain HIV load in AIDS. Brain Pathol 1998;8:277-284. (Pubitemid 28186065)
156. Gelman BB, Nguyen TP. Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes. J Neuroimmune Pharmacol 2010;5:92-102.
157. Ferris MJ, Frederick-Duus D, Fadel J, et al. In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission. Synapse 2009;63:181-185.
158. Gelman BB, Spencer JA, Holzer CE III, Soukup VM. Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis. J Neuroimmune Pharmacol 2006;1:410-420.
159. Maragos WF, Tillman P, Jones M, et al. Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, Tat. Neuroscience 2003;117:43-53.
160. Norman JP, Perry SW, Reynolds HM, et al. HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization. PLoS One 2008;3:e3731.
161. Kim HJ, Martemyanov KA, Thayer SA. Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. J Neurosci 2008;28:12604-12613.
162. Haughey NJ, Steiner J, Nath A, et al. Converging roles for sphingolipids and cell stress in the progression of neuro-AIDS. Front Biosci 2008;13:5120-5130. (Pubitemid 351599662)
163. Steiner J, Haughey N, Li W, et al. Oxidative stress and therapeutic approaches in HIV dementia. Antioxid Redox Signal 2006;8:2089-2100. (Pubitemid 46489633)
164. Meisner F, Neuen-Jacob E, Sopper S, et al. Disruption of excitatory amino acid transporters in brains of SIV-infected rhesus macaques is associated with microglia activation. J Neurochem 2008;104:202-209. (Pubitemid 350265063)
165. Ferrando S, Rabkin J, van Gorp W, McElhiney M. Protease inhibitors are associated with less neuropsychological impairment in HIV infection. Abstract presented at: 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, IL.
166. Sacktor NC, Skolasky RL, Lyles RH, et al. Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J Neurovirol 2000;6:84-88. (Pubitemid 30175576)
167. Sacktor N, Nakasujja N, Wong M, et al. HAART improves neurocognitive impairment in HIV+ individuals in Uganda. Abstract presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 23, 2005; Boston, MA.
168. Clifford DB, Simpson D. Targeting HIV therapy for the brain. HIV Adv Res Ther 1998;8:10-17.
169. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-294.
170. Clifford DB. Human immunodeficiency virus-associated dementia. Arch Neurol 2000;57:321-324.
171. Sacktor N, Tarwater PM, Skolasky RL, et al. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology 2001;57:542-544.
172. Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 2004;61:1699-1704.
173. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23:1359-1366.
174. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70.
175. Cunningham PH, Smith DG, Satchell C, et al. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000;14:1949-1954.
176. Cinque P, Presi S, Bestetti A, et al. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retroviruses 2001;17:377-383.
177. Lanier ER, Sturge G, McClernon D, et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS 2001;15:747-751.
178. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007;45:174-182. (Pubitemid 46869810)
179. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009;73:342-348.
180. Tozzi V, Balestra P, Galgani S, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 1999;13:1889-1897.
181. Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005;293:2003-2011.
182. Sacktor N, Schifitto G, McDermott MP, et al. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000;54:233-235.
183. Schifitto G, Kieburtz K, McDermott MP, et al. Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology 2001;56:415-418.
184. Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009;72:1458-1464.
185. Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 2007;21:1877-1886.
186. Rumbaugh JA, Steiner J, Sacktor N, Nath A. Developing neuro-protective strategies for treatment of HIV-associated neurocognitive dysfunction. Futur HIV Ther 2008;2:271-280.
187. Brew BJ, Crowe SM, Landay A, et al. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 2009;4:163-174.